Cyrus Mozayeni follows ADC ‘beacon’ to Pheon CEO role; BeiGene loses business chief to Teva

Cyrus Moza­yeni has been around the biotech busi­ness long enough not to be fazed when things don’t go as ex­pect­ed.

Soon af­ter he closed his last start­up in April, Vedere Bio II — a gene ther­a­py biotech born out of an­oth­er that was sold to No­var­tis — he re­turned to his net­work at At­las Ven­ture, where he is en­tre­pre­neur-in-res­i­dence, to scout new op­por­tu­ni­ties. Ear­li­er this month, he start­ed a new job as CEO of Pheon Ther­a­peu­tics to re­place Bertrand Damour at the At­las-backed com­pa­ny.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN